What cases are to be reported?
The Louisiana Tumor Registry requires that all in situ and invasive neoplasms (cancers with behavior codes 2 or 3 in the ICD-O-3 manual) be reported.
Carcinoid, NOS of the appendix is reportable, effective January 1, 2015, forward
Please note: the ICD-O-3 behavior code has changed from /1 to /3.
All Squamous Intraepithelial Neoplasias, grade III (SIN III) are reportable to the Louisiana Tumor Registry, including (but not limited to):
- Anal Intraepithelial Neoplasia (AIN III–C21.0-C21.1)
- Exception: AIN III (8077) arising in perianal skin (C445) is non-reportable
- Cervical intraepithelial neoplasia (CIN III–C53.0-C53.9, effective January 1. 2009 forward). Please see CIN III Reporting Details
- Conjunctival intraepithelial neoplasia/lesion (CIN III-C69.0)
- Laryngeal Intraepithelial neoplasia (LIN III—C32.0-C32.9)
- Lobular Neoplasia, grade III (LN III), effective January 1, 2016, forward
- Lobular Intraepithelial neoplasia, grade III (LIN III), effective January 1, 2016, forward
- Penile Intraepithelial neoplasia, grade III (PeIN III—C600-C609), effective January 1, 2016, forward
- Vaginal intra-epithelial neoplasia (VAIN III—C52.9)
- Vulvar intraepithelial neoplasia (VIN III—C51.0-C51.9)
Carcinoma in situ (CIS) of the cervix –effective January 1, 2009 forward, please see CIN III Reporting Details
All tumors of the brain and central nervous system (site codes C70.0-C72.9 and C75.1-C75.3 in the ICD-O-3 code book) are to be reported, regardless of behavior code. Juvenile astrocytomas should be reported as M9421/3. (Benign brain and CNS tumors are reportable effective January 1, 2004.)
Positive urine cytologies: Effective 2013, these should be reported if they document the presence of “positive malignant cells” or “(malignant) cells interpreted as carcinoma” and should be coded to C68.9 Urinary System NOS in the absence of any other information on the site of origin.
Two exceptions to the instructions about reporting positive urine cytologies:
1. If the positive urine cytology is later followed by a negative tissue biopsy of a urinary site, DO NOT REPORT, as the pathology proved the cytology to be incorrect. The pathologic diagnosis is the “gold standard.” When cytology and pathology disagree, always use the pathology. (SEER SINQ 20100106 & 20120079)
2. Urine cytologies utilizing ambiguous terminology are not reportable. For example, do not report a urine cytology that is “suspicious for malignant cells.”
The following are not reportable:
- Prostatic intraepithelial neoplasia, grade III (PIN III—after 1/1/2001)
- Squamous intraepithelial neoplasia of the cervix (CIN III—effective 1996-2008 only)
- Skin cancers (C44._ range only) with histologies 8000-8005, 8010-8046, 8050-8084, and 8090-8110. These include, but are not limited to, basal cell and squamous cell carcinomas of the skin.
Note 1: All skin cancers (C44._ range) with histologies other than those listed above must be reported.
Note 2: Skin cancers, regardless of histology, must be reported if they are not in the C44._ range. This includes the following:
- Skin of the labia majoria, C51.0
- Skin of the penis C60.9
- Skin of the scrotum C63.2
- Skin of the vulva C51.9
- Certain Hematopoietic Diseases–there are several Hematopoietic diseases that are similar to reportable Hematopoietic neoplasms. An alphabetical list of these non-reportable hematopoietic terms is available here.
Additional Reporting Clarifications
The Resourceful Registrar section of this website includes many reporting and coding clarifications, as well as, manual references for abstracting cancer cases.